Market Overview:
A solid tumor can characterized by growth of abnormal mass or lump of
tissues without liquid or cysts. It is classified into malignant tumor
(cancerous) and the benign tumor (non-cancerous). Additionally, based on the
cell type, tumors can be classified as sarcomas, carcinomas, and lymphomas.
Key Market Drivers:
Growing popularity of biosimilars therapies is driving growth of the solidtumors treatment market. Moreover, rising prevalence of solid tumors is fueling
market growth. According to the Centers for Disease Control and Prevention, in the
United States in 2019, 1,752,735 new cancer cases were reported and 599,589
people died of cancer. For every 100,000 people, 439 new cancer cases were
reported and 146 people died of cancer.
Growing merger &acquisition in the market of cancer therapies by key
players is again contributing to market growth. For instance, in July 2022, Takeda announced that it has acquire Adaptate
Biotherapeutics to develop novel Gamma Delta (γδ) T Cell Engager therapies
targeting solid tumors.
Comments
Post a Comment